
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular Inc. demonstrated a robust financial performance with a significant 47% year-over-year increase in operating income, reaching $18.8 million, complemented by a strong adjusted gross margin of 70.4%. The company reported an impressive 14% organic revenue growth driven by a combination of 9% price and 5% volume increases, while adjusted EPS rose by 23%. Additionally, regional sales exhibited strong momentum, particularly in EMEA and APAC markets, further strengthening the overall growth outlook for the company.
Bears say
LeMaitre Vascular Inc faces a challenging outlook due to potential technical problems with its mRidium pump, unexpected competition, and possible regulatory issues with the FDA that could significantly impair financial performance. Additionally, the company has identified risks such as lower price increases, competitive pressures, slower international market adoption, and delays in regulatory approvals that may negatively influence its financial position. Finally, while general and administrative expenses were slightly lower than expected at 16.1% of revenue, any failure to meet revenue forecasts could adversely affect the company's shares.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares